Kinetics of hematological and biochemical biomarkers are key tools for monitoring disease progression in Marburg virus-infected patients in Rwanda
Marburg Virus Disease (MVD) is a severe disease with a fatality rate of up to 90%. Limited studies have suggested hematological and biochemical biomarkers for managing MVD, but data on key markers correlated with MVD development are scarce. This study aimed to investigate the biosignatures that can...
Saved in:
| Published in | Scientific reports Vol. 15; no. 1; pp. 21405 - 9 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
London
Nature Publishing Group UK
01.07.2025
Nature Publishing Group Nature Portfolio |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Marburg Virus Disease (MVD) is a severe disease with a fatality rate of up to 90%. Limited studies have suggested hematological and biochemical biomarkers for managing MVD, but data on key markers correlated with MVD development are scarce. This study aimed to investigate the biosignatures that can be used to monitor MVD progression in Marburg virus (MARV)-infected patients. We performed a retrospective analysis of biochemical and hematological data collected from 51 MARV-infected patients in Rwanda. The study subjects were classified according to the day of discharge: early (< 5 days), middle (5–10 days) and late recovery (> 10 days). Our data revealed that Aspartate transaminase (AST), Alanine transaminase (ALT)), and creatinine were significantly lower in MVD-recovered subjects as compared to newly admitted patients (
p
< 0.0001 each). Lymphocytes and platelets were increased in MVD-recovered subjects (
p
< 0.0001 and
p
< 0.001, respectively). ALT levels discriminated between middle, late recovered individuals, and MVD patients (AUC: 0.86, 0.90, 0.94, respectively). AST also showed strong discriminatory power for middle, late recovery, and MVD patients (AUC: 0.81, 0.95, 0.94, respectively). Similarly platelets differentiated the middle, late MVD-recovered groups and MVD patients (AUC: 0.79,0.61, 0.90, respectively). Creatinine and lymphocytes were also suggested as potential biomarkers for MVD development. These findings provide novel insights into biological factors crucial for MVD management. Although all investigated biomarkers can be used to monitor MVD patients, our analyses highlight key biosignatures that can guide clinicians to track MVD progression and enable real-time decisions. |
|---|---|
| AbstractList | Abstract Marburg Virus Disease (MVD) is a severe disease with a fatality rate of up to 90%. Limited studies have suggested hematological and biochemical biomarkers for managing MVD, but data on key markers correlated with MVD development are scarce. This study aimed to investigate the biosignatures that can be used to monitor MVD progression in Marburg virus (MARV)-infected patients. We performed a retrospective analysis of biochemical and hematological data collected from 51 MARV-infected patients in Rwanda. The study subjects were classified according to the day of discharge: early (< 5 days), middle (5–10 days) and late recovery (> 10 days). Our data revealed that Aspartate transaminase (AST), Alanine transaminase (ALT)), and creatinine were significantly lower in MVD-recovered subjects as compared to newly admitted patients (p < 0.0001 each). Lymphocytes and platelets were increased in MVD-recovered subjects (p < 0.0001 and p < 0.001, respectively). ALT levels discriminated between middle, late recovered individuals, and MVD patients (AUC: 0.86, 0.90, 0.94, respectively). AST also showed strong discriminatory power for middle, late recovery, and MVD patients (AUC: 0.81, 0.95, 0.94, respectively). Similarly platelets differentiated the middle, late MVD-recovered groups and MVD patients (AUC: 0.79,0.61, 0.90, respectively). Creatinine and lymphocytes were also suggested as potential biomarkers for MVD development. These findings provide novel insights into biological factors crucial for MVD management. Although all investigated biomarkers can be used to monitor MVD patients, our analyses highlight key biosignatures that can guide clinicians to track MVD progression and enable real-time decisions. Marburg Virus Disease (MVD) is a severe disease with a fatality rate of up to 90%. Limited studies have suggested hematological and biochemical biomarkers for managing MVD, but data on key markers correlated with MVD development are scarce. This study aimed to investigate the biosignatures that can be used to monitor MVD progression in Marburg virus (MARV)-infected patients. We performed a retrospective analysis of biochemical and hematological data collected from 51 MARV-infected patients in Rwanda. The study subjects were classified according to the day of discharge: early (< 5 days), middle (5–10 days) and late recovery (> 10 days). Our data revealed that Aspartate transaminase (AST), Alanine transaminase (ALT)), and creatinine were significantly lower in MVD-recovered subjects as compared to newly admitted patients ( p < 0.0001 each). Lymphocytes and platelets were increased in MVD-recovered subjects ( p < 0.0001 and p < 0.001, respectively). ALT levels discriminated between middle, late recovered individuals, and MVD patients (AUC: 0.86, 0.90, 0.94, respectively). AST also showed strong discriminatory power for middle, late recovery, and MVD patients (AUC: 0.81, 0.95, 0.94, respectively). Similarly platelets differentiated the middle, late MVD-recovered groups and MVD patients (AUC: 0.79,0.61, 0.90, respectively). Creatinine and lymphocytes were also suggested as potential biomarkers for MVD development. These findings provide novel insights into biological factors crucial for MVD management. Although all investigated biomarkers can be used to monitor MVD patients, our analyses highlight key biosignatures that can guide clinicians to track MVD progression and enable real-time decisions. Marburg Virus Disease (MVD) is a severe disease with a fatality rate of up to 90%. Limited studies have suggested hematological and biochemical biomarkers for managing MVD, but data on key markers correlated with MVD development are scarce. This study aimed to investigate the biosignatures that can be used to monitor MVD progression in Marburg virus (MARV)-infected patients. We performed a retrospective analysis of biochemical and hematological data collected from 51 MARV-infected patients in Rwanda. The study subjects were classified according to the day of discharge: early (< 5 days), middle (5-10 days) and late recovery (> 10 days). Our data revealed that Aspartate transaminase (AST), Alanine transaminase (ALT)), and creatinine were significantly lower in MVD-recovered subjects as compared to newly admitted patients (p < 0.0001 each). Lymphocytes and platelets were increased in MVD-recovered subjects (p < 0.0001 and p < 0.001, respectively). ALT levels discriminated between middle, late recovered individuals, and MVD patients (AUC: 0.86, 0.90, 0.94, respectively). AST also showed strong discriminatory power for middle, late recovery, and MVD patients (AUC: 0.81, 0.95, 0.94, respectively). Similarly platelets differentiated the middle, late MVD-recovered groups and MVD patients (AUC: 0.79,0.61, 0.90, respectively). Creatinine and lymphocytes were also suggested as potential biomarkers for MVD development. These findings provide novel insights into biological factors crucial for MVD management. Although all investigated biomarkers can be used to monitor MVD patients, our analyses highlight key biosignatures that can guide clinicians to track MVD progression and enable real-time decisions. Marburg Virus Disease (MVD) is a severe disease with a fatality rate of up to 90%. Limited studies have suggested hematological and biochemical biomarkers for managing MVD, but data on key markers correlated with MVD development are scarce. This study aimed to investigate the biosignatures that can be used to monitor MVD progression in Marburg virus (MARV)-infected patients. We performed a retrospective analysis of biochemical and hematological data collected from 51 MARV-infected patients in Rwanda. The study subjects were classified according to the day of discharge: early (< 5 days), middle (5-10 days) and late recovery (> 10 days). Our data revealed that Aspartate transaminase (AST), Alanine transaminase (ALT)), and creatinine were significantly lower in MVD-recovered subjects as compared to newly admitted patients (p < 0.0001 each). Lymphocytes and platelets were increased in MVD-recovered subjects (p < 0.0001 and p < 0.001, respectively). ALT levels discriminated between middle, late recovered individuals, and MVD patients (AUC: 0.86, 0.90, 0.94, respectively). AST also showed strong discriminatory power for middle, late recovery, and MVD patients (AUC: 0.81, 0.95, 0.94, respectively). Similarly platelets differentiated the middle, late MVD-recovered groups and MVD patients (AUC: 0.79,0.61, 0.90, respectively). Creatinine and lymphocytes were also suggested as potential biomarkers for MVD development. These findings provide novel insights into biological factors crucial for MVD management. Although all investigated biomarkers can be used to monitor MVD patients, our analyses highlight key biosignatures that can guide clinicians to track MVD progression and enable real-time decisions.Marburg Virus Disease (MVD) is a severe disease with a fatality rate of up to 90%. Limited studies have suggested hematological and biochemical biomarkers for managing MVD, but data on key markers correlated with MVD development are scarce. This study aimed to investigate the biosignatures that can be used to monitor MVD progression in Marburg virus (MARV)-infected patients. We performed a retrospective analysis of biochemical and hematological data collected from 51 MARV-infected patients in Rwanda. The study subjects were classified according to the day of discharge: early (< 5 days), middle (5-10 days) and late recovery (> 10 days). Our data revealed that Aspartate transaminase (AST), Alanine transaminase (ALT)), and creatinine were significantly lower in MVD-recovered subjects as compared to newly admitted patients (p < 0.0001 each). Lymphocytes and platelets were increased in MVD-recovered subjects (p < 0.0001 and p < 0.001, respectively). ALT levels discriminated between middle, late recovered individuals, and MVD patients (AUC: 0.86, 0.90, 0.94, respectively). AST also showed strong discriminatory power for middle, late recovery, and MVD patients (AUC: 0.81, 0.95, 0.94, respectively). Similarly platelets differentiated the middle, late MVD-recovered groups and MVD patients (AUC: 0.79,0.61, 0.90, respectively). Creatinine and lymphocytes were also suggested as potential biomarkers for MVD development. These findings provide novel insights into biological factors crucial for MVD management. Although all investigated biomarkers can be used to monitor MVD patients, our analyses highlight key biosignatures that can guide clinicians to track MVD progression and enable real-time decisions. Marburg Virus Disease (MVD) is a severe disease with a fatality rate of up to 90%. Limited studies have suggested hematological and biochemical biomarkers for managing MVD, but data on key markers correlated with MVD development are scarce. This study aimed to investigate the biosignatures that can be used to monitor MVD progression in Marburg virus (MARV)-infected patients. We performed a retrospective analysis of biochemical and hematological data collected from 51 MARV-infected patients in Rwanda. The study subjects were classified according to the day of discharge: early (< 5 days), middle (5–10 days) and late recovery (> 10 days). Our data revealed that Aspartate transaminase (AST), Alanine transaminase (ALT)), and creatinine were significantly lower in MVD-recovered subjects as compared to newly admitted patients (p < 0.0001 each). Lymphocytes and platelets were increased in MVD-recovered subjects (p < 0.0001 and p < 0.001, respectively). ALT levels discriminated between middle, late recovered individuals, and MVD patients (AUC: 0.86, 0.90, 0.94, respectively). AST also showed strong discriminatory power for middle, late recovery, and MVD patients (AUC: 0.81, 0.95, 0.94, respectively). Similarly platelets differentiated the middle, late MVD-recovered groups and MVD patients (AUC: 0.79,0.61, 0.90, respectively). Creatinine and lymphocytes were also suggested as potential biomarkers for MVD development. These findings provide novel insights into biological factors crucial for MVD management. Although all investigated biomarkers can be used to monitor MVD patients, our analyses highlight key biosignatures that can guide clinicians to track MVD progression and enable real-time decisions. |
| ArticleNumber | 21405 |
| Author | Kayigi, Etienne Ntagwabira, Edward Seruyange, Eric Ngabonziza, Jean Claude Semuto Mutesa, Leon Mukagatare, Isabelle Tuyishime, Albert Rujeni, Nadine Makayoto, Lyndah Muvunyi, Claude Mambo Gahamanyi, Noel Rwagasore, Edison Nkeshimana, Menelas Twagirumugabe, Theogene Uwayo, Henri Desire Harelimana, Jean de Dieu Mugisha, Jean Claude Gashema, Pierre Turatsinze, David Umwanankabandi, Fidele Gashegu, Misbah Musafiri, Sanctus |
| Author_xml | – sequence: 1 givenname: Jean Claude surname: Mugisha fullname: Mugisha, Jean Claude organization: College of Medicine and Health Sciences, University of Rwanda – sequence: 2 givenname: Etienne surname: Kayigi fullname: Kayigi, Etienne organization: Rwanda Biomedical Center, Rwanda National Joint Task Force Marburg, Rwanda Biomedical Centre, Ministry of Health – sequence: 3 givenname: Noel surname: Gahamanyi fullname: Gahamanyi, Noel organization: Rwanda Biomedical Center, Rwanda National Joint Task Force Marburg, Rwanda Biomedical Centre, Ministry of Health – sequence: 4 givenname: Henri Desire surname: Uwayo fullname: Uwayo, Henri Desire organization: Rwanda Biomedical Center, Rwanda National Joint Task Force Marburg, Rwanda Biomedical Centre, Ministry of Health – sequence: 5 givenname: Fidele surname: Umwanankabandi fullname: Umwanankabandi, Fidele organization: Rwanda Biomedical Center, Rwanda National Joint Task Force Marburg, Rwanda Biomedical Centre, Ministry of Health – sequence: 6 givenname: Pierre surname: Gashema fullname: Gashema, Pierre organization: Rwanda National Joint Task Force Marburg, Rwanda Biomedical Centre, Ministry of Health – sequence: 7 givenname: Edison surname: Rwagasore fullname: Rwagasore, Edison organization: Rwanda Biomedical Center, Rwanda National Joint Task Force Marburg, Rwanda Biomedical Centre, Ministry of Health – sequence: 8 givenname: David surname: Turatsinze fullname: Turatsinze, David organization: Butare University Teaching Hospital, Kigali University Teaching Hospital – sequence: 9 givenname: Menelas surname: Nkeshimana fullname: Nkeshimana, Menelas organization: Ministry of Health, Rwanda National Joint Task Force Marburg, Rwanda Biomedical Centre, Ministry of Health – sequence: 10 givenname: Misbah surname: Gashegu fullname: Gashegu, Misbah organization: Rwanda Biomedical Center – sequence: 11 givenname: Edward surname: Ntagwabira fullname: Ntagwabira, Edward organization: Rwanda Biomedical Center – sequence: 12 givenname: Lyndah surname: Makayoto fullname: Makayoto, Lyndah organization: World Health Organization – sequence: 13 givenname: Jean Claude Semuto surname: Ngabonziza fullname: Ngabonziza, Jean Claude Semuto organization: Rwanda Biomedical Center – sequence: 14 givenname: Isabelle surname: Mukagatare fullname: Mukagatare, Isabelle organization: Rwanda Biomedical Center, Rwanda National Joint Task Force Marburg, Rwanda Biomedical Centre, Ministry of Health – sequence: 15 givenname: Albert surname: Tuyishime fullname: Tuyishime, Albert organization: Rwanda Biomedical Center – sequence: 16 givenname: Nadine surname: Rujeni fullname: Rujeni, Nadine organization: World Health Organization – sequence: 17 givenname: Leon surname: Mutesa fullname: Mutesa, Leon organization: College of Medicine and Health Sciences, University of Rwanda – sequence: 18 givenname: Eric surname: Seruyange fullname: Seruyange, Eric organization: Rwanda Military Hospital, Rwanda National Joint Task Force Marburg, Rwanda Biomedical Centre, Ministry of Health – sequence: 19 givenname: Sanctus surname: Musafiri fullname: Musafiri, Sanctus organization: College of Medicine and Health Sciences, University of Rwanda, Kigali University Teaching Hospital – sequence: 20 givenname: Theogene surname: Twagirumugabe fullname: Twagirumugabe, Theogene organization: Butare University Teaching Hospital, Rwanda National Joint Task Force Marburg, Rwanda Biomedical Centre, Ministry of Health – sequence: 21 givenname: Jean de Dieu surname: Harelimana fullname: Harelimana, Jean de Dieu organization: World Health Organization – sequence: 22 givenname: Claude Mambo surname: Muvunyi fullname: Muvunyi, Claude Mambo email: claude.muvunyi@rbc.gov.rw organization: Rwanda Biomedical Center, Rwanda National Joint Task Force Marburg, Rwanda Biomedical Centre, Ministry of Health |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/40593942$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9Uk1v1DAQjVARLaV_gAOyxIVLwB7bSXxCqCpQUYSE4Gw5zjj1NmsvdlLUv8EvxrtbSssBXzwev3nz9Z5WByEGrKrnjL5mlHdvsmBSdTUFWVPRcqi7R9URUCFr4AAH9-zD6iTnFS1HghJMPakOBZWKKwFH1a9PPuDsbSbRkUtcmzlOcfTWTMSEgfQ-2uLdvYu9NukKUyYmIbnCGzLHOGXiYiLrGPwckw8jGXxGk5FsUhwT5uxjID6Qzyb1SxrJtU9Lrn1waGccyMbMHsOct5CvP0tO86x67MyU8eT2Pq6-vz_7dvqxvvjy4fz03UVthRJz7RoujBiYaV0jmIMWetpaazvpWhCsQdNSN1BwYDvTd0qiUaxry_CAIx-QH1fne94hmpXeJF-6u9HReL1zxDRqk8poJtSgmhYZ623nQAxD03e2jLK1AqRSJXHhervn2iz9GgdbOkpmekD68Cf4Sz3Ga80AmGoYFIZXtwwp_lgwz3rts8VpMgHjknVZZMOl5Kwt0Jf_QFdxSaHMqqA4bbjisimoF_dLuqvlz-4LAPYAm2LOCd0dhFG91Zjea0wXjemdxnRXgvg-KG-2y8b0N_d_on4DKX7WDA |
| Cites_doi | 10.1016/S0733-8627(20)30997-4 10.1016/j.ijid.2025.107902 10.1038/s41598-021-89340-y 10.1038/s41467-024-46226-7 10.2217/fvl.11.79 10.1038/s42255-022-00652-3 10.1038/nri2098 10.1128/JVI.01643-14 10.1136/pgmj.49.574.542 10.3389/fimmu.2018.03071 10.1128/JVI.00126-09 10.1186/s12985-019-1272-z 10.1016/j.virusres.2024.199337 10.1126/scitranslmed.aai8711 10.3390/diseases12120309 10.1016/j.clinpr.2024.100392 10.1093/infdis/jiy457 10.1136/bmj.4.5995.489 10.3389/fmed.2021.705247 10.1093/infdis/jiv095 10.1093/infdis/jiab552 10.1016/j.jhepr.2021.100258 10.1093/infdis/jiad362 10.1371/journal.pntd.0002858 10.1038/labinvest.3780021 10.1093/infdis/jiy293 10.1186/s12879-024-09508-5 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2025 2025. The Author(s). The Author(s) 2025. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2025 2025 |
| Copyright_xml | – notice: The Author(s) 2025 – notice: 2025. The Author(s). – notice: The Author(s) 2025. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2025 2025 |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88A 88E 88I 8FE 8FH 8FI 8FJ 8FK ABUWG AEUYN AFKRA AZQEC BBNVY BENPR BHPHI CCPQU COVID DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M1P M2P M7P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS Q9U 7X8 5PM DOA |
| DOI | 10.1038/s41598-025-04732-8 |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Biology Database (Alumni Edition) Medical Database (Alumni Edition) Science Database (Alumni Edition) ProQuest SciTech Collection ProQuest Natural Science Journals Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central (New) Natural Science Collection ProQuest One Coronavirus Research Database ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) ProQuest Biological Science Collection ProQuest Health & Medical Collection Medical Database Science Database Biological Science Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Central China ProQuest Biology Journals (Alumni Edition) ProQuest Central ProQuest One Applied & Life Sciences ProQuest One Sustainability ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Central Basic ProQuest Science Journals ProQuest One Academic Eastern Edition Coronavirus Research Database ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 5 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 2045-2322 |
| EndPage | 9 |
| ExternalDocumentID | oai_doaj_org_article_2967e11bc8f24dd6b8c2947c4259972b PMC12219612 40593942 10_1038_s41598_025_04732_8 |
| Genre | Journal Article |
| GeographicLocations | Rwanda |
| GeographicLocations_xml | – name: Rwanda |
| GroupedDBID | 0R~ 4.4 53G 5VS 7X7 88E 88I 8FE 8FH 8FI 8FJ AAFWJ AAJSJ AAKDD AASML ABDBF ABUWG ACGFS ACUHS ADBBV ADRAZ AENEX AEUYN AFKRA AFPKN ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BBNVY BCNDV BENPR BHPHI BPHCQ BVXVI C6C CCPQU DIK DWQXO EBD EBLON EBS ESX FYUFA GNUQQ GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE KQ8 LK8 M1P M2P M7P M~E NAO OK1 PHGZM PHGZT PIMPY PPXIY PQGLB PQQKQ PROAC PSQYO RNT RNTTT RPM SNYQT UKHRP AAYXX CITATION PJZUB CGR CUY CVF ECM EIF NPM 3V. 7XB 88A 8FK COVID K9. M48 PKEHL PQEST PQUKI PRINS Q9U 7X8 PUEGO 5PM |
| ID | FETCH-LOGICAL-c494t-f634a4d1a7f641f272b07ccc85f72416ea70fd02f2c8ab895ea918710323e3de3 |
| IEDL.DBID | C6C |
| ISSN | 2045-2322 |
| IngestDate | Wed Aug 27 01:30:15 EDT 2025 Thu Aug 21 18:33:37 EDT 2025 Tue Aug 26 08:58:13 EDT 2025 Sat Aug 23 13:29:49 EDT 2025 Fri Jul 18 01:41:19 EDT 2025 Thu Jul 24 01:51:07 EDT 2025 Thu Jul 17 02:05:40 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Biomarkers Kinetics Marburg virus Disease progression Rwanda |
| Language | English |
| License | 2025. The Author(s). Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c494t-f634a4d1a7f641f272b07ccc85f72416ea70fd02f2c8ab895ea918710323e3de3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | https://www.nature.com/articles/s41598-025-04732-8 |
| PMID | 40593942 |
| PQID | 3230639356 |
| PQPubID | 2041939 |
| PageCount | 9 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_2967e11bc8f24dd6b8c2947c4259972b pubmedcentral_primary_oai_pubmedcentral_nih_gov_12219612 proquest_miscellaneous_3226355317 proquest_journals_3230639356 pubmed_primary_40593942 crossref_primary_10_1038_s41598_025_04732_8 springer_journals_10_1038_s41598_025_04732_8 |
| PublicationCentury | 2000 |
| PublicationDate | 2025-07-01 |
| PublicationDateYYYYMMDD | 2025-07-01 |
| PublicationDate_xml | – month: 07 year: 2025 text: 2025-07-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Scientific reports |
| PublicationTitleAbbrev | Sci Rep |
| PublicationTitleAlternate | Sci Rep |
| PublicationYear | 2025 |
| Publisher | Nature Publishing Group UK Nature Publishing Group Nature Portfolio |
| Publisher_xml | – name: Nature Publishing Group UK – name: Nature Publishing Group – name: Nature Portfolio |
| References | C Woolsey (4732_CR12) 2018; 218 4732_CR18 H Fausther-Bovendo (4732_CR22) 2022; 225 M Mohamadzadeh (4732_CR23) 2007; 7 CM Muvunyi (4732_CR4) 2024; 12 A Marzi (4732_CR14) 2019; 22 JC Guito (4732_CR6) 2024; 15 CE Mire (4732_CR13) 2017 JL Lyman (4732_CR29) 1986; 4 B Koch (4732_CR24) 2024; 342 H Pott-Junior (4732_CR26) 2021; 15 E Kinyenje (4732_CR1) 2024; 24 4732_CR2 M Mehedi (4732_CR7) 2011; 6 KL Warfield (4732_CR17) 2009; 83 N Shafran (4732_CR28) 2021; 3 X Qiu (4732_CR16) 2014; 88 JS Gear (4732_CR10) 1975; 4 J Wagner (4732_CR27) 2021; 11 B Wafula Simiyu (4732_CR3) 2024; 24 GA Martini (4732_CR9) 1973; 49 O Nsekuye (4732_CR30) 2025; 156 JC Zapata (4732_CR31) 2014; 8 C Atkins (4732_CR19) 2018 TW Geisbert (4732_CR11) 2000; 80 4732_CR20 K Shifflett (4732_CR8) 2019; 16 L Fernando (4732_CR15) 2015; 212 P ClovisS (4732_CR25) 2022; 4 ER Glaze (4732_CR5) 2015; 65 LC Dupuy (4732_CR21) 2023; 228 |
| References_xml | – volume: 4 start-page: 223 issue: 2 year: 1986 ident: 4732_CR29 publication-title: Emerg. Med. Clin. N. Am. doi: 10.1016/S0733-8627(20)30997-4 – volume: 156 start-page: 107902 year: 2025 ident: 4732_CR30 publication-title: Int. J. Infect. Dis. doi: 10.1016/j.ijid.2025.107902 – ident: 4732_CR18 – volume: 11 start-page: 10308 issue: 1 year: 2021 ident: 4732_CR27 publication-title: Sci. Rep. doi: 10.1038/s41598-021-89340-y – volume: 65 start-page: 241 issue: 3 year: 2015 ident: 4732_CR5 publication-title: Comp. Med. – volume: 15 start-page: 1826 issue: 1 year: 2024 ident: 4732_CR6 publication-title: Nat. Commun. doi: 10.1038/s41467-024-46226-7 – volume: 6 start-page: 1091 issue: 9 year: 2011 ident: 4732_CR7 publication-title: Future Virol. doi: 10.2217/fvl.11.79 – volume: 4 start-page: 1245 issue: 10 year: 2022 ident: 4732_CR25 publication-title: Nat. Metab. doi: 10.1038/s42255-022-00652-3 – volume: 7 start-page: 556 issue: 7 year: 2007 ident: 4732_CR23 publication-title: Nat. Rev. Immunol. doi: 10.1038/nri2098 – ident: 4732_CR20 – volume: 88 start-page: 12703 issue: 21 year: 2014 ident: 4732_CR16 publication-title: J. Virol. doi: 10.1128/JVI.01643-14 – volume: 49 start-page: 542 issue: 574 year: 1973 ident: 4732_CR9 publication-title: Postgrad. Med. J. doi: 10.1136/pgmj.49.574.542 – volume: 22 start-page: 3071 issue: 9 year: 2019 ident: 4732_CR14 publication-title: Front. Immunol. doi: 10.3389/fimmu.2018.03071 – volume: 83 start-page: 6404 issue: 13 year: 2009 ident: 4732_CR17 publication-title: J. Virol. doi: 10.1128/JVI.00126-09 – volume: 16 start-page: 165 issue: 1 year: 2019 ident: 4732_CR8 publication-title: Virol. J. doi: 10.1186/s12985-019-1272-z – volume: 342 start-page: 199337 year: 2024 ident: 4732_CR24 publication-title: Virus Res. doi: 10.1016/j.virusres.2024.199337 – ident: 4732_CR2 – year: 2017 ident: 4732_CR13 publication-title: Sci. Transl. Med. doi: 10.1126/scitranslmed.aai8711 – volume: 12 start-page: 309 issue: 12 year: 2024 ident: 4732_CR4 publication-title: Diseases doi: 10.3390/diseases12120309 – volume: 24 start-page: 100392 year: 2024 ident: 4732_CR3 publication-title: Clin. Infect. Pract. doi: 10.1016/j.clinpr.2024.100392 – year: 2018 ident: 4732_CR19 publication-title: J. Infect. Dis. doi: 10.1093/infdis/jiy457 – volume: 4 start-page: 489 issue: 5995 year: 1975 ident: 4732_CR10 publication-title: BMJ doi: 10.1136/bmj.4.5995.489 – volume: 15 start-page: 705247 issue: 8 year: 2021 ident: 4732_CR26 publication-title: Front. Med. doi: 10.3389/fmed.2021.705247 – volume: 212 start-page: S234 issue: suppl 2 year: 2015 ident: 4732_CR15 publication-title: J. Infect. Dis. doi: 10.1093/infdis/jiv095 – volume: 225 start-page: 1852 issue: 10 year: 2022 ident: 4732_CR22 publication-title: J. Infect. Dis. doi: 10.1093/infdis/jiab552 – volume: 3 start-page: 100258 issue: 3 year: 2021 ident: 4732_CR28 publication-title: JHEP Rep. doi: 10.1016/j.jhepr.2021.100258 – volume: 228 start-page: S446 issue: Supplement_6 year: 2023 ident: 4732_CR21 publication-title: J. Infect. Dis. doi: 10.1093/infdis/jiad362 – volume: 8 start-page: e2858 issue: 6 year: 2014 ident: 4732_CR31 publication-title: PLoS Neglect. Trop. Dis. doi: 10.1371/journal.pntd.0002858 – volume: 80 start-page: 171 issue: 2 year: 2000 ident: 4732_CR11 publication-title: Lab Invest. doi: 10.1038/labinvest.3780021 – volume: 218 start-page: S582 issue: suppl_5 year: 2018 ident: 4732_CR12 publication-title: J. Infect. Dis. doi: 10.1093/infdis/jiy293 – volume: 24 start-page: 628 issue: 1 year: 2024 ident: 4732_CR1 publication-title: BMC Infect. Dis. doi: 10.1186/s12879-024-09508-5 |
| SSID | ssj0000529419 |
| Score | 2.450709 |
| Snippet | Marburg Virus Disease (MVD) is a severe disease with a fatality rate of up to 90%. Limited studies have suggested hematological and biochemical biomarkers for... Abstract Marburg Virus Disease (MVD) is a severe disease with a fatality rate of up to 90%. Limited studies have suggested hematological and biochemical... |
| SourceID | doaj pubmedcentral proquest pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Publisher |
| StartPage | 21405 |
| SubjectTerms | 692/53 692/700 Adult Alanine transaminase Alanine Transaminase - blood Aspartate Aminotransferases - blood Aspartate transaminase Biomarkers Biomarkers - blood Blood Blood platelets Creatinine Creatinine - blood Cytokines Disease Progression Electrolytes Enzymes Fatalities Female Hematology Hemoglobin Humanities and Social Sciences Humans Infections Kinetics Leukocytes Liver Lymphocytes Male Marburg disease Marburg virus Marburg Virus Disease - blood Marburg Virus Disease - diagnosis Marburg Virus Disease - virology Marburgvirus Middle Aged multidisciplinary Pathogenesis Platelets Principal components analysis Retrospective Studies Rwanda Rwanda - epidemiology Science Science (multidisciplinary) Viruses Young Adult |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Li9RAEG5kQfAivo2u0oI3DduvJN1HFZdFWQ_iwt6aTj90wE2WyYzL_g1_sVXdmXHHB1685dGEouvZqaqvCHneGPAKoXF19IzBAcXHGvyMrlVotGO9b5PAfufjD-3RiXp32pxeGfWFNWEFHrhs3IEwbRc5771OQoXQ9toLozoPsoY9nz1aX_B5Vw5TBdUbFnEzd8kwqQ8moAm7yURTM9VJMAM7nigD9v8pyvy9WPKXjGl2RIe3yM05gqSvCuW3ybU43CHXy0zJy7vk-3uIGxF7mY6JZkTWjXmjbgi0X-CIrIwRgNdnWJ2znKhbRgrqTFfj-HWiEMjSs6zsSAKdkzg013IVHA-6GOixQ458pt8Wy_VUl6quGOiM1Drhko8X-KPiHjk5fPvpzVE9D16ovTJqVadWKqcCd11qFU8Ctpl13nvdpA48fhtdx1JgIgmvXa9NE53hcPJiUsgoQ5T3yd4wDvEhocazPgQwE97Bt-EGPoC5xCAab3jkFXmxYYI9L_gaNufFpbaFZRZYZjPLrK7Ia-TTdiViY-cHIDF2lhj7L4mpyP6Gy3ZW2MlKPIphm3JbkWfb16BqmD9xQxzXuAaRe8BodRV5UIRiS4nC0YhGiYroHXHZIXX3zbD4kuG8uQCvAYFmRV5uJOsnXX_fi0f_Yy8ekxsiqwTWH--TvdVyHZ9AlLXqn2aF-gHwrSUR priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwEB5BERIXxJtAQUbiBlEdx4mdEwJEVYHKAVFpb5ZjO2WlNinJLoi_wS9mxvFutbxueVjRJPOMZ-YbgOdVg17BVzYPjnP8QXEhRz-jc-krbXnr6k5Qv_Pxx_roRL5fVIu04TalssqNTYyG2g-O9sgPSoqVqY-0fnXxNaepUZRdTSM0rsI1gi6jki61UNs9FspiyaJJvTK81AcTUkY9ZaLKuVQlGoMdfxRh-_8Wa_5ZMvlb3jS6o8NbcDPFkez1zPjbcCX0d-D6PFnyx134-QGjR0JgZkPHIi7rxsgx23vWLmlQVkQKoONzqtEZJ2bHwFCp2WoYziaG4Sw7jypPJLCUymGxomtG82DLnh1b4ssp-7Yc11M-13YFzxJe60RLPn2n7Yp7cHL47vPbozyNX8idbOQq7-pSWukLq7paFp1QouXKOaerTqHfr4NVvPNcdMJp2-qmCrYp8P-LI6tC6UN5H_b6oQ8PgTWOt96jsXAWn40n-ADKKHpRuaYIRQYvNkwwFzPKhonZ8VKbmWUGWWYiy4zO4A3xabuSELLjhWE8NUnhjGhqFYqidboT0vu61Q6FQTm0UdQr3Gawv-GySWo7mUshy-DZ9jYqHGVRbB-GNa0h_B40XSqDB7NQbCmRNCCxkSIDvSMuO6Tu3umXXyKodyHQd2C4mcHLjWRd0vXvb_Ho_6_xGG6IKOxUX7wPe6txHZ5gFLVqn0ZV-QX6dx0U priority: 102 providerName: ProQuest |
| Title | Kinetics of hematological and biochemical biomarkers are key tools for monitoring disease progression in Marburg virus-infected patients in Rwanda |
| URI | https://link.springer.com/article/10.1038/s41598-025-04732-8 https://www.ncbi.nlm.nih.gov/pubmed/40593942 https://www.proquest.com/docview/3230639356 https://www.proquest.com/docview/3226355317 https://pubmed.ncbi.nlm.nih.gov/PMC12219612 https://doaj.org/article/2967e11bc8f24dd6b8c2947c4259972b |
| Volume | 15 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwED_tQ0i8IL4JjMpIvEFE4jix89hVm6aiTWgwqW-WYzujEktQ04L4N_iLuXOSosJ44Klp4lin3Kd9dz8DvM5L9AouN7G3SYILFOtj9DMqFi5XJqlsUXPqdz6_KM6uxHyRL_aAj70woWg_QFoGMz1Wh73rcEpqBuN5nAiZoRbvwyFBt5NUz4rZdl-FMlciLYf-mCRTt7y644MCVP9t8eXfZZJ_5EqDCzq9D_eG2JFNe2ofwJ5vHsKd_jTJH4_g53uMGAl1mbU1C1iso2FjpnGsWtLhWAEdgK5vqC5n1TGz8gwVma3b9kvHMIRlN0HNiQQ2pG9YqOLqETzYsmHnhnhxzb4tV5su7uu5vGMDRmtHQy6_0xbFY7g6Pfk0O4uHIxdiK0qxjusiE0a41Mi6EGnNJa8Saa1VeS3R1xfeyKR2Ca-5VaZSZe5NmeKaK8l45jPnsydw0LSNfwastEnlHBoIa3Bu_IMTUBbR8dyWqU8jeDMyQX_tkTV0yIhnSvcs08gyHVimVQTHxKftSELFDjfa1bUepETzspA-TSurai6cKyplURikRbtE_cFVBEcjl_Wgqp3OaBFGDcpFBK-2j1HJKHNiGt9uaAxh9qC5khE87YViS4mgQxFLwSNQO-KyQ-ruk2b5OQB5pxz9BYaYEbwdJes3Xf_-Fs__b_gLuMuD8FON8REcrFcb_xIjqXU1gX25kBM4nE7nH-f4e3xy8eFyEhRqEnYnfgHHVR_u |
| linkProvider | Springer Nature |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VrRBcEG8CBYwEJ4iaOE7iHBCi0GrLdleoaqXeUsd2yko0KZtdqv4Nfgi_kRkn2Wp53XrLw7ImmfE3Y88L4GWcoVYwsfKtDgLcoGjro56RvjCxVEGhk5JTvvN4kgwPxaej-GgNfva5MBRW2WOiA2pTazoj34zIVqY80uTd2TefukaRd7VvodGKxchenOOWrXm7-xH5-4rzne2DD0O_6yrga5GJuV8mkVDChCotExGWPOVFkGqtZVymqM4Sq9KgNAEvuZaqkFlsVRbitiJACmxkbITzXoN1EeFWZgDrW9uTz_vLUx3ym4kw67JzgkhuNvgvKIuNx34g0gjhZ0UDukYBf7Nu_wzS_M1T6xTgzm241Vmu7H0randgzVZ34Xrby_LiHvwYob1KNZ9ZXTJXCbaHVaYqw4opteZytQno-pSigmYNUzPLEEbYvK6_NgwNaHbqQIZIYJ3ziLkYsrZ-CJtWbKxIEk7Y9-ls0fhtNJk1rKsQ29CQ_XM6ILkPh1fCmgcwqOrKPgKW6aAwBuFJK5wbb3AC8mEaHusstKEHr3sm5GdtXY_c-eMjmbcsy5FluWNZLj3YIj4tR1JNbvegnp3k3RLPeZakNgwLLUsujEkKqVEYUo2oSNnJhQcbPZfzDiia_FKsPXixfI1LnPw2qrL1gsZQxSAEy9SDh61QLCkR1JIxE9wDuSIuK6SuvqmmX1wZ8ZCjtkID14M3vWRd0vXvf_H4_5_xHG4MD8Z7-d7uZPQEbnIn-BTdvAGD-Wxhn6INNy-edQuHwfFVr9VfIxFbFQ |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwED-NIRAviG8CA4wETxA1cZw4eUAIGNVG2YQQk_pmHNsZlVgympZp_wZ_Dn8dd07SqXy97a1tLOuau_vd2fcF8CQt0CrYVIfORBEeUIwL0c7kobBprqPSZBWneue9_WznQLybptMN-DnUwlBa5YCJHqhtY-iOfJSQr0x1pNmo6tMiPmyPXx5_C2mCFEVah3EanYhM3OkJHt_aF7vbyOunnI_ffnqzE_YTBkIjCrEIqywRWthYyyoTccUlLyNpjMnTSqJpy5yWUWUjXnGT6zIvUqeLGI8YEVLjEusS3PcCXJRJGpOOyalc3e9QBE3ERV-nEyX5qMW3QvVsPA0jIRMEojVb6EcG_M3P_TNd87eYrTeF42twtfdh2atO6K7DhqtvwKVuquXpTfgxQc-Vuj-zpmK-J-wAsEzXlpUzGtLluxTQ5yPKD5q3TM8dQ0Bhi6b52jJ0pdmRhxsigfVhJOazybpOImxWsz1NMnHIvs_myzbs8sqcZX2v2JaWfDyhq5JbcHAujLkNm3VTu7vAChOV1iJQGY174xfcgKKZlqemiF0cwLOBCeq46_ChfGQ-yVXHMoUsU55lKg_gNfFptZK6c_sfmvmh6pVd8SKTLo5Lk1dcWJuVuUFhkAbxkeqUywC2Bi6rHjJadSbgATxePUZlpwiOrl2zpDXUOwhhUwZwpxOKFSWChjMWggeQr4nLGqnrT-rZF99QPOZot9DVDeD5IFlndP37Xdz7_994BJdRQ9X73f3JfbjCvdxTmvMWbC7mS_cAnblF-dBrDYPP562mvwBW9V3l |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Kinetics+of+hematological+and+biochemical+biomarkers+are+key+tools+for+monitoring+disease+progression+in+Marburg+virus-infected+patients+in+Rwanda&rft.jtitle=Scientific+reports&rft.au=Mugisha%2C+Jean+Claude&rft.au=Kayigi%2C+Etienne&rft.au=Gahamanyi%2C+Noel&rft.au=Uwayo%2C+Henri+Desire&rft.date=2025-07-01&rft.pub=Nature+Publishing+Group+UK&rft.eissn=2045-2322&rft.volume=15&rft.issue=1&rft_id=info:doi/10.1038%2Fs41598-025-04732-8&rft.externalDocID=10_1038_s41598_025_04732_8 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2045-2322&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2045-2322&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2045-2322&client=summon |